Liver Cancer Therapeutics Market size was over USD 2.99 billion in 2023 and is anticipated to reach USD 26.87 billion by 2036, witnessing around 18.4% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of liver cancer therapeutics is estimated at USD 3.43 billion. The growth of the market is attributed to growing prevalence of liver cancer over high alcohol consumption, non-alcoholic fatty liver disease, and rise in incidence of hepatitis B infection in developing countries. According to the World Health Organisation, liver cancer was ranked third in the most common causes of cancer death in the world in 2020, causing nearly 830,000 deaths, while in 2019, hepatitis B resulted in an estimated 820,000 deaths globally.
Moreover, increasing R&D activities and advancement in cancer therapeutics with emergence of targeted therapies, and increasing public awareness leading to higher demand for treatment are further expected to foster the growth of the market.
However, high cost and side effects related to certain liver cancer therapies, such as gastrointestinal diseases, hair loss, fatigue, skin diseases, etc. are one of the key factors restraining the growth of the market. Moreover, limitations in treatment options with several therapies in clinical trial stage are further expected to hinder the market growth.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024–2036 |
|
CAGR |
18.4% |
|
Base Year Market Size (2023) |
USD 2.99 billion |
|
Forecast Year Market Size (2036) |
USD 26.87 billion |
|
Regional Scope |
|
The market is segmented by type into hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and others, out of which, the hepatocellular carcinoma segment is anticipated to hold the largest market share owing to being the most common type of liver cancer and is caused mainly due to alcohol abuse.
On the basis of therapy, the liver cancer therapeutics market is segmented into targeted therapy, radiation therapy, immunotherapy, chemotherapy, and others. Targeted therapy eliminates the side effects associated with other cancer therapies and targeted therapy drugs are largely recommended by healthcare providers. Owing to these factors, the targeted therapy segment is estimated to grow at the highest rate over the forecast period. Furthermore, there are various targeted therapy clinical trials that are ongoing, while several are getting approved as treatment methods rapidly. These factors are further expected to drive the growth of the segment.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Therapy |
|
Geographically, the global liver cancer therapeutics market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. North America region is expected to hold largest industry share by 2036, owing to high awareness about liver cancer, presence of well-established healthcare infrastructure, and easy drug availability. According to the U.S. Centers for Disease Control & Prevention (CDC), around 24,500 men and 10,000 women get affected from liver cancer every year in the U.S., while about 18,600 men and 9,000 women die from the disease.
Asia-Pacific region is projected to witness growth at the highest rate over the forecast period on the back of rapid increase in the liver cancer patients in the region, mainly in highly populated countries, such as India & China, and advancing healthcare. According to the World Cancer Research Fund (WCRF), Mongolia had the highest rate of liver cancer in the world in 2018, while Thailand, China, and South Korea ranked at 8th, 9th, and 10th respectively.
June 2019: Exelixis, Inc. announced that CABOMETYX tablets have been approved by the U.S. Food and Drug Administration (FDA) for patients with hepatocellular carcinoma (HCC), previously treated with sorafenib.
May 2019: Eli Lilly and Company announced that their CYRAMZA has become the first U.S. FDA-approved biomarker-driven therapy for the second-line treatment of patients with hepatocellular carcinoma (HCC). This approval has been noted as an important step forward in the treatment of advanced hepatocellular carcinoma.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?